Eric Joseph
Stock Analyst at JP Morgan
(1.41)
# 2,870
Out of 4,862 analysts
134
Total ratings
38.37%
Success rate
-10.63%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $46.96 | +36.29% | 3 | Jun 3, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $1.46 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $2.93 | +1,401.71% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $6.94 | +0.86% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $51.25 | +30.73% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.33 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.38 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $11.93 | +151.47% | 7 | Jan 29, 2025 | |
| IGMS IGM Biosciences | Upgrades: Neutral | n/a | $1.21 | - | 8 | Jan 13, 2025 | |
| VIR Vir Biotechnology | Maintains: Neutral | $10 → $14 | $5.22 | +168.20% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $40.59 | +74.92% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $43 | $36.01 | +19.41% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $10.17 | +273.65% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $1.55 | +1,383.87% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $6.96 | +144.43% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $3.22 | +552.17% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $48 | $17.06 | +181.36% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $7.49 | +33.60% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.85 | - | 4 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $2.36 | +535.59% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $1.68 | +257.14% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $4.92 | +103.25% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $4.91 | +124.03% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $55.62 | -26.29% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $9.91 | +909.59% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.58 | +768.96% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.16 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $3.88 | +183.51% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.10 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $4.39 | +2,633.49% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $7.71 | +3,791.05% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.40 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $6.16 | +711.69% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $2.12 | +324.53% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.56 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.31 | +1,718.18% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $0.62 | +1,996.77% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.49 | +2,140.33% | 3 | Nov 14, 2018 |
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $46.96
Upside: +36.29%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $2.93
Upside: +1,401.71%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $6.94
Upside: +0.86%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $51.25
Upside: +30.73%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.33
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $11.93
Upside: +151.47%
IGM Biosciences
Jan 13, 2025
Upgrades: Neutral
Price Target: n/a
Current: $1.21
Upside: -
Vir Biotechnology
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $5.22
Upside: +168.20%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $40.59
Upside: +74.92%
Nov 25, 2024
Maintains: Overweight
Price Target: $30 → $43
Current: $36.01
Upside: +19.41%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $10.17
Upside: +273.65%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $1.55
Upside: +1,383.87%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $6.96
Upside: +144.43%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $3.22
Upside: +552.17%
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $17.06
Upside: +181.36%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $7.49
Upside: +33.60%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.85
Upside: -
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $2.36
Upside: +535.59%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $1.68
Upside: +257.14%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $4.92
Upside: +103.25%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $4.91
Upside: +124.03%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $55.62
Upside: -26.29%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $9.91
Upside: +909.59%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.58
Upside: +768.96%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.16
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $3.88
Upside: +183.51%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $9.10
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $4.39
Upside: +2,633.49%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $7.71
Upside: +3,791.05%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.40
Upside: -
Jul 12, 2021
Initiates: Neutral
Price Target: $50
Current: $6.16
Upside: +711.69%
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $2.12
Upside: +324.53%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.56
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.31
Upside: +1,718.18%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $0.62
Upside: +1,996.77%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.49
Upside: +2,140.33%